Pages that link to "Q124936536"

The following pages link to Koichi Minato (Q124936536):

Displaying 26 items.

• Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer (Q33409629) (← links)
• Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer (Q37389608) (← links)
• Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer (Q37692130) (← links)
• Clinical significance of post-progression survival in lung cancer (Q38669447) (← links)
• High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma (Q38760585) (← links)
• Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy (Q38852314) (← links)
• Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis. (Q39143953) (← links)
• Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide (Q39572955) (← links)
• Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors (Q41143898) (← links)
• First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations (Q41503002) (← links)
• A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients (Q41537638) (← links)
• Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer (Q45300017) (← links)
• Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer (Q48016072) (← links)
• The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer. (Q52672760) (← links)
• Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. (Q54111653) (← links)
• Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis (Q57042202) (← links)
• Prognostic Significance of Glucose Metabolism as GLUT1 in Patients with Pulmonary Pleomorphic Carcinoma (Q89578443) (← links)
• Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC (Q90050696) (← links)
• A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations (Q90345398) (← links)
• Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer (Q90472668) (← links)
• Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors (Q90942768) (← links)
• An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer (Q92048751) (← links)
• Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer (Q92103898) (← links)
• Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study (Q93093206) (← links)
• Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (Q97561643) (← links)
• Post-progression survival is strongly linked to overall survival in refractory small-cell lung cancer patients who received amrubicin (Q99544146) (← links)